Deutsche Bank Aktiengesellschaft Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)

Analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $31.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 48.47% from the stock’s current price.

DNLI has been the topic of a number of other reports. Robert W. Baird started coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target on the stock. JPMorgan Chase & Co. decreased their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Jefferies Financial Group boosted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.42.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $20.88 on Tuesday. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33. The company has a market cap of $3.01 billion, a PE ratio of -7.57 and a beta of 1.43. The stock’s 50 day moving average price is $22.10 and its 200 day moving average price is $24.82.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the transaction, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 over the last three months. 7.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. CWM LLC increased its stake in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the last quarter. Creative Planning boosted its position in shares of Denali Therapeutics by 40.0% in the third quarter. Creative Planning now owns 60,254 shares of the company’s stock worth $1,755,000 after buying an additional 17,221 shares during the period. nVerses Capital LLC purchased a new stake in shares of Denali Therapeutics in the third quarter worth about $288,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Denali Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,535 shares of the company’s stock worth $802,000 after buying an additional 10,782 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.